Risperdal Lawsuits

Risperdal, an antipsychotic medication, has been tied to a serious adverse reactions in boys and men known as gynecomastia—male breast growth. Individuals who have developed this painful and embarrassing condition are encouraged to consider filing a Risperdal lawsuit to obtain compensation for their suffering. Janssen Pharmaceuticals, the Johnson & Johnson unit that manufactures and markets Risperdal, is facing mounting litigation over gynecomastia claims filed on behalf of boys and men who now suffer from male breast growth, lactation, and the need for surgeries, such as liposuction and mastectomy, to remove excess breast tissue.

Bernstein Liebhard LLP is offering free Risperdal case evaluations to anyone who may have developed gynecomastia due to this medication.  If you or someone you love might be a victim of Risperdal gynecomastia, please contact the Firm today to learn more about your legal options concerning the filing of a Risperdal claim.

How Risperdal is Prescribed

An atypical antipsychotic prescribed for the treatment of schizophrenia and bipolar disorder in adults and adolescents, Risperdal is also approved for the treatment of irritability in pediatric patients—children 5-16 years of age—who are diagnosed with autistic disorder. Risperdal is also used off-label to treat attention deficit hyperactivity disorder (ADHD). Risperdal received U.S. Food and Drug Administration approval in 1993, but the drug was not cleared for any pediatric uses until 2006.

Risperdal and other atypical antipsychotics are designed to target the brain’s serotonin and dopamine receptors. Since its approval, Risperdal has been tied to an array of significant side effects, including Risperdal gynecomastia, Type 2 diabetes, and movement disorders.

Risperdal Legal ActionTied to Gynecomastia

Lawsuits filed on behalf of Risperdal patients who allegedly developed gynecomastia due to the drug claim it has caused men and boys to suffer:

  • Swelling of breast tissue
  • Breast tenderness
  • Breast pain
  • Nipple discharge from one or both breasts

Various studies have revealed an association between the use of Risperdal and gynecomastia. In 2006, one study published in the Journal of Clinical Psychopharmacology revealed that some children who took Risperdal developed elevated prolactin levels. Prolactin is a hormone associated with the development of breasts in girls as well as lactation in new mothers. Another study, published in 2009 in the Journal of Child and Adolescent Psychopharmacology, revealed that the increased prolactin levels seen in Risperdal patients could continue for up to two years.

Mounting Risperdal claims have been filed nationwide over allegations that Johnson & Johnson and its Janssen unit knew that taking Risperdal could lead to gynecomastia, yet concealed that knowledge from the public. In October 2012 Bloomberg News reported  the drug makers began settling some lawsuits pending in a consolidated litigation that was underway in the Philadelphia Court of Common Pleas in Pennsylvania. At that time, five settlements were reached on behalf of boys who allegedly developed gynecomastia due to Risperdal.

In November 2012, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle criminal and civil charges with the federal government involving the marketing of Risperdal and other drugs. Among other things, the U.S. Department of Justice also charged that the drug maker illegally marketed Risperdal for children well before the drug was approved for use in pediatric patients.

Suing for Risperdal Complications

The Risperdal attorneys at Bernstein Liebhard LLP are available to assist you, or your loved ones, in obtaining compensation for the pain and suffering caused by gynecomastia that may be associated with the use of this drug. To learn more about your options for pursuing a Risperdal lawsuit, please contact Bernstein Liebhard LLP today by calling 1-855-511-1001.

Do I Have a Case?

  • For a free and confidential Risperdal case evaluation, please complete this form and we will contact you shortly.
  • This field is for validation purposes and should be left unchanged.